Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21895684 | 0.92 | NT5E (0.53) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL12151598 | 0.87 | HPRT1 (0.61) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL12154664 | 0.87 | HPRT1 (0.61) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL3759846 | 0.87 | HPRT1 (0.61) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL12154815 | 0.85 | POLB (0.57) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL12151602 | 0.85 | POLB (0.57) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL2922052 | 0.84 | POLB (0.61) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL20442307 | 0.84 | POLB (0.61) | POLBNT5EFUT5PNPSTING1 | |
| Phosphoric Acid SCHEMBL16213328 | 0.82 | NT5E (0.54) | POLBNT5EFUT5PNPSTING1 | |
| SCHEMBL12300885 | 0.82 | NT5E (0.51) | POLBNT5EFUT5PNPSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020057546-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | 上海迪诺医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | POLB 3320/4885NT5E 3116/4885FUT5 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.